Effect of Rifampin on the Pharmacokinetics of BAY73-4506

Inclusion Criteria

• •Healthy male subject
• •Age: 18 to 45 years (inclusive) at the first screening examination / visit
• •Body mass index (BMI): 18 to 32 kg/m² (inclusive)
• •Ability to understand and follow study-related instructions
• •Subjects enrolled in this study must use adequate barrier birth control measures prior to, during the course of the study, and 3 months after the last administration of regorafenib. An adequate contraception includes the use of condoms or a vasectomy. In addition, adequate birth control measures for the subject's partner is required, such as a hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices, bilateral tubal ligation, or hysterectomy.